Effect of cisapride therapy for severe dyspepsia on gastrointestinal symptoms and quality of life

General discussion

T. L. Abell, T. F. Cutts, Terrance Cooper

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Quality of life measures have received little attention in evaluation of therapy for dyspepsia. To examine the effect of cisapride on gastrointestinal symptoms and quality of life measures, we studied eight patients with chronic, severe dyspepsia, before and after therapy with cisapride (20 mg three times daily) for 12 months. Gastrointestinal (GI) Total Symptom Score (TSS), Overall Patient Assessment (OPA), and quality of life by both trait (Minnesota Multiphasic Personality Inventory (MMPI)) and physical function (Sickness Impact Profile (SIP)) were measured at base line and at month 12 of cisapride therapy. Results showed significant improvement in TSS, OPA, and the MMPI Depression and Anxiety scales (all, p < 0.05). Improvement in the SIP physical dimension score approached significance (p = 0.065). We conclude that, in this group of patients with severe dyspepsia, both GI symptoms and quality of life measures improved with 12 months of cisapride therapy. These quality of life measures may prove useful in evaluating the efficacy of drug treatment for dyspepsia.

Original languageEnglish (US)
Pages (from-to)60-64
Number of pages5
JournalScandinavian Journal of Gastroenterology
Volume28
Issue numberS195
DOIs
StatePublished - Jan 1 1993

Fingerprint

Cisapride
Dyspepsia
Quality of Life
Sickness Impact Profile
MMPI
Therapeutics
Anxiety
Depression
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Gastroenterology

Cite this

Effect of cisapride therapy for severe dyspepsia on gastrointestinal symptoms and quality of life : General discussion. / Abell, T. L.; Cutts, T. F.; Cooper, Terrance.

In: Scandinavian Journal of Gastroenterology, Vol. 28, No. S195, 01.01.1993, p. 60-64.

Research output: Contribution to journalArticle

@article{0cbd9c05aea548e9b2528e3855e32bd6,
title = "Effect of cisapride therapy for severe dyspepsia on gastrointestinal symptoms and quality of life: General discussion",
abstract = "Quality of life measures have received little attention in evaluation of therapy for dyspepsia. To examine the effect of cisapride on gastrointestinal symptoms and quality of life measures, we studied eight patients with chronic, severe dyspepsia, before and after therapy with cisapride (20 mg three times daily) for 12 months. Gastrointestinal (GI) Total Symptom Score (TSS), Overall Patient Assessment (OPA), and quality of life by both trait (Minnesota Multiphasic Personality Inventory (MMPI)) and physical function (Sickness Impact Profile (SIP)) were measured at base line and at month 12 of cisapride therapy. Results showed significant improvement in TSS, OPA, and the MMPI Depression and Anxiety scales (all, p < 0.05). Improvement in the SIP physical dimension score approached significance (p = 0.065). We conclude that, in this group of patients with severe dyspepsia, both GI symptoms and quality of life measures improved with 12 months of cisapride therapy. These quality of life measures may prove useful in evaluating the efficacy of drug treatment for dyspepsia.",
author = "Abell, {T. L.} and Cutts, {T. F.} and Terrance Cooper",
year = "1993",
month = "1",
day = "1",
doi = "10.3109/00365529309098330",
language = "English (US)",
volume = "28",
pages = "60--64",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "S195",

}

TY - JOUR

T1 - Effect of cisapride therapy for severe dyspepsia on gastrointestinal symptoms and quality of life

T2 - General discussion

AU - Abell, T. L.

AU - Cutts, T. F.

AU - Cooper, Terrance

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Quality of life measures have received little attention in evaluation of therapy for dyspepsia. To examine the effect of cisapride on gastrointestinal symptoms and quality of life measures, we studied eight patients with chronic, severe dyspepsia, before and after therapy with cisapride (20 mg three times daily) for 12 months. Gastrointestinal (GI) Total Symptom Score (TSS), Overall Patient Assessment (OPA), and quality of life by both trait (Minnesota Multiphasic Personality Inventory (MMPI)) and physical function (Sickness Impact Profile (SIP)) were measured at base line and at month 12 of cisapride therapy. Results showed significant improvement in TSS, OPA, and the MMPI Depression and Anxiety scales (all, p < 0.05). Improvement in the SIP physical dimension score approached significance (p = 0.065). We conclude that, in this group of patients with severe dyspepsia, both GI symptoms and quality of life measures improved with 12 months of cisapride therapy. These quality of life measures may prove useful in evaluating the efficacy of drug treatment for dyspepsia.

AB - Quality of life measures have received little attention in evaluation of therapy for dyspepsia. To examine the effect of cisapride on gastrointestinal symptoms and quality of life measures, we studied eight patients with chronic, severe dyspepsia, before and after therapy with cisapride (20 mg three times daily) for 12 months. Gastrointestinal (GI) Total Symptom Score (TSS), Overall Patient Assessment (OPA), and quality of life by both trait (Minnesota Multiphasic Personality Inventory (MMPI)) and physical function (Sickness Impact Profile (SIP)) were measured at base line and at month 12 of cisapride therapy. Results showed significant improvement in TSS, OPA, and the MMPI Depression and Anxiety scales (all, p < 0.05). Improvement in the SIP physical dimension score approached significance (p = 0.065). We conclude that, in this group of patients with severe dyspepsia, both GI symptoms and quality of life measures improved with 12 months of cisapride therapy. These quality of life measures may prove useful in evaluating the efficacy of drug treatment for dyspepsia.

UR - http://www.scopus.com/inward/record.url?scp=0027273639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027273639&partnerID=8YFLogxK

U2 - 10.3109/00365529309098330

DO - 10.3109/00365529309098330

M3 - Article

VL - 28

SP - 60

EP - 64

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - S195

ER -